PeptideScanner retained ClinicalTrials.gov record NCT01524705 at 2026-07-30T19:03:45.487Z. Its registry update date was 2023-12-29, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00868283 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-12-15, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03795701 at 2026-07-30T19:03:45.488Z. Its registry update date was 2023-12-04, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00818623 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-30, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT00819156 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-30, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT04290429 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-11-29, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02381249 at 2026-07-30T19:04:52.219Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02385617 at 2026-07-30T19:04:52.214Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00819247 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-09, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT06106932 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-30, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02150954 at 2026-11-16T00:59:19.138Z. Its registry update date was 2023-10-26, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT05199714 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-25, and PeptideScanner's reviewed identity mapping was pramlintide.
PeptideScanner retained ClinicalTrials.gov record NCT03426761 at 2026-11-15T22:01:45.056Z. Its registry update date was 2023-10-03, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT04525157 at 2026-07-30T19:08:50.172Z. Its registry update date was 2023-09-22, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03960437 at 2026-11-15T22:07:29.454Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT02896192 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03737240 at 2026-07-30T19:08:50.174Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05407597 at 2026-11-15T22:04:12.435Z. Its registry update date was 2023-09-07, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT03953131 at 2026-11-16T17:36:42.191Z. Its registry update date was 2023-09-01, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT00002889 at 2026-07-30T19:09:38.368Z. Its registry update date was 2023-08-18, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03389412 at 2026-11-16T01:33:21.554Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT04026256 at 2026-07-30T19:09:38.366Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04879420 at 2026-07-30T19:10:42.715Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04897958 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04436497 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-07-25, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT03331289 at 2026-07-30T19:10:42.713Z. Its registry update date was 2023-07-24, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03169166 at 2026-11-15T21:49:16.513Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT02981069 at 2026-07-30T19:10:42.759Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01364584 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-12, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00571727 at 2026-11-16T17:35:13.282Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT03525613 at 2026-11-16T01:37:14.654Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT02527200 at 2026-07-30T19:10:42.748Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00427349 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-05, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03043664 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01841359 at 2026-07-30T19:11:49.725Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was pramlintide.
PeptideScanner retained ClinicalTrials.gov record NCT00003057 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-18, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00003283 at 2026-07-30T19:11:49.727Z. Its registry update date was 2023-06-15, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02431325 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-06-12, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04652479 at 2026-11-16T01:46:44.871Z. Its registry update date was 2023-06-09, and PeptideScanner's reviewed identity mapping was avexitide.
PeptideScanner retained ClinicalTrials.gov record NCT04605861 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-07, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03404661 at 2026-11-16T01:34:15.953Z. Its registry update date was 2023-06-06, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT02333565 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-25, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02384122 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-24, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03287960 at 2026-07-30T19:13:03.752Z. Its registry update date was 2023-05-23, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03572088 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-22, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT03072147 at 2026-07-30T19:13:03.748Z. Its registry update date was 2023-05-12, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01779362 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04859322 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02025179 at 2026-07-30T19:13:03.751Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02058706 at 2026-07-30T19:13:03.747Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03822091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-09, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT03664180 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-05-03, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT01416649 at 2026-07-30T19:14:02.187Z. Its registry update date was 2023-04-26, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT05807503 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-04-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT04962503 at 2026-07-30T19:14:02.188Z. Its registry update date was 2023-04-11, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT02867267 at 2026-11-15T22:10:40.222Z. Its registry update date was 2023-04-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT03512262 at 2026-07-30T19:14:02.186Z. Its registry update date was 2023-04-07, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04416282 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-04-06, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00432172 at 2026-11-15T21:50:32.222Z. Its registry update date was 2023-04-03, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT04172987 at 2026-07-30T19:15:14.513Z. Its registry update date was 2023-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT03940742 at 2026-07-30T19:15:14.510Z. Its registry update date was 2023-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT03596164 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-03-15, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00001259 at 2026-07-30T19:15:14.515Z. Its registry update date was 2023-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03895697 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04589819 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-13, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT05368857 at 2026-07-30T19:16:22.169Z. Its registry update date was 2023-02-09, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT04836273 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-02, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03318393 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-01-31, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT03472846 at 2026-07-30T19:17:35.707Z. Its registry update date was 2023-01-26, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02440581 at 2026-07-30T19:17:35.692Z. Its registry update date was 2023-01-05, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04830943 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-01-03, and PeptideScanner's reviewed identity mapping was cerebrolysin.